InSite Vision Incorporated (InSite) is an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company�s portfolio of products is based on its DuraSite sustained drug delivery technology. The Company has focused its research and development and commercial support efforts on the topical products formulated with its DuraSite drug delivery technology, which include AzaSite, Besivance, AzaSite Plus, DexaSite, BromSit, DuraSite and ISV-101. AzaSite (azithromycin ophthalmic solution) 1% is a DuraSite formulation of azithromycin, a broad spectrum ocular antibiotic approved by the United States Food and Drug Administration (FDA) to treat bacterial conjunctivitis (pink eye). Besivance (besifloxacin ophthalmic suspension) 0.6% is a DuraSite formulation of besifloxacin, a spectrum ocular antibiotic approved by the FDA to treat bacterial conjunctivitis (pink eye).